Home › All Companies › COAG › Current Report

Hemab Therapeutics Holdings, Inc. (COAG) — Current Report

AI-Powered SEC Filing Analysis

← All COAG filings
Latest Current Report Filed: 2026-05-11

Key Insights

  • Board member Dr. Laura Tadvalkar resigned effective immediately on May 8, 2026, reducing board representation, though the company explicitly stated the departure was unrelated to operational disagreements or disputes.
  • The resignation was characterized as non-contentious with no disclosed conflicts over company operations, policies, or practices, suggesting an amicable departure rather than a governance concern.
  • As an emerging growth company, Hemab Therapeutics has flexibility in governance requirements, but the loss of a board member may impact oversight capacity depending on total board size and remaining expertise.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-11. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-04
  • Hemab Therapeutics completed its IPO on May 4, 2026, raising $346.7 million in gross proceeds at $18.00 per share, including full exercise of underwriter options for 19.3 million shares.
  • The company implemented anti-takeover protections including a classified board with staggered three-year terms, 75% supermajority vote requirement for director removal, and elimination of stockholder written consent rights.
  • The Restated Certificate authorizes 400 million common shares and 5 million undesignated preferred shares, significantly increasing capital structure flexibility post-IPO.
  • Delaware Court of Chancery is designated as exclusive forum for internal corporate claims, while federal courts handle securities law claims, limiting stockholder litigation venue options.
Sentiment: Positive Significance: 8/10
View Original Filing →

Other reports for Hemab Therapeutics Holdings, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.